Neuroendocrine Tumor Treatments and Follow-up Disease Management: Comparative Perspective (US and Canada vs Global) (2022) Kolarova T, Hollander R, Mcdonnell M, Bouvier C, Pavel ME, Singh H, Howe J, et al. Conference contribution [Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study (2022) Singh S, Pavel ME, Kunz PL, De Herder W, Herrmann K, D'Amelio AM, Santoro P, et al. Conference contribution Plasma Metabolic Profiling Identify Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma (2021) Mahajan UM, Alnatsha A, Li Q, Oehrle B, Weiss U, Sendler M, Distler M, et al. Conference contribution Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) - USA and Canada vs Global Diagnosis of NETs (2021) Gellerman E, Herman J, Mcdonnell M, Van Genechten D, Pavel ME, O'Toole D, Singh H, et al. Conference contribution Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study (2021) Pavel ME, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies (2021) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Journal article Development and Validation of a Multivariable Prediction Model Based on Blood Plasma and Serum Metabolomics for the Diagnosis of Chronic Pancreatitis (2020) Beyer G, Adam MG, Christiansen N, Kamlage B, Pilarsky C, Distler M, Falbusch T, et al. Conference contribution Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms (2020) Merola E, Dal Buono A, Denecke T, Arsenic R, Pape UF, Jann H, Wiedenmann B, Pavel ME Journal article CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen (2020) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Xuan-Mai Truong Thanh , et al. Conference contribution Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials (2019) Anthony L, Kulke M, Caplin M, Bergsland E, Oberg K, Pavel ME, Horsch D, et al. Conference contribution